Halozyme Therapeutics (HALO) Liabilities and Shareholders Equity (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $2.7 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 21.68% year-over-year to $2.7 billion in Q1 2026; TTM through Mar 2026 was $9.5 billion, a 13.49% increase from a year earlier, with the FY2025 full-year figure at $2.5 billion, up 22.38% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $2.7 billion, up from $2.5 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for HALO reached as high as $2.7 billion in Q1 2026 and fell as low as $1.2 billion in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2023.
• Across the five-year window, Liabilities and Shareholders Equity soared 73.65% in 2022 and declined 5.88% in 2023, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.8 billion in 2022, then decreased by 5.88% to $1.7 billion in 2023, then climbed by 19.05% to $2.1 billion in 2024, then advanced by 22.38% to $2.5 billion in 2025, then gained by 5.84% to $2.7 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $2.7 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.2 billion in Q3 2025.